|本期目录/Table of Contents|

[1]王玲华,冯梅,钟沛霖,等.宫颈癌同步放化疗患者血清鳞状细胞相关抗原水平变化及意义[J].慢性病学杂志,2019,20(08):1133-1136.
　WANGLing-hua,FENGMei,ZHONGPei-lin,et al.Clinical significance of serum levels of squamous cell carcinoma antigen in patients with cervical cancer receiving chemoradiotherapy[J].,2019,20(08):1133-1136.
点击复制

宫颈癌同步放化疗患者血清鳞状细胞相关抗原水平变化及意义(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年08期
页码:
1133-1136
栏目:
论　著
出版日期:
2019-07-28

文章信息/Info

Title:
Clinical significance of serum levels of squamous cell carcinoma antigen in patients with cervical cancer receiving chemoradiotherapy
作者:
王玲华; 冯梅; 钟沛霖; 郭爱华
福建省肿瘤医院妇科肿瘤，福州 350014
Author(s):
WANGLing-hua; FENGMei; ZHONGPei-lin; GUOAi-hua
FujianCancerHospital&FujianMedicalUniversityCancerHospital,Fuzhou350014,China Correspondingauthor:FENGMei,E-mail:m13810494080@163.com
关键词:
宫颈癌; 血清鳞状细胞癌相关抗原; 同步放化疗; 疗效
Keywords:
Cervical cancer;  Squamous cell carcinoma antigen;  Chemoradiotherapy;  Curative effects
分类号:
R737.33
DOI:
-
摘要:
目的 观察宫颈癌同步放化疗患者放化疗前后血清鳞状细胞癌相关抗原（SCC）水平变化，探讨其水平 与肿瘤负荷、近期疗效之间的关系。方法 回顾性分析142例宫颈癌初治患者的临床资料，采集所有患者治疗 前后的血清标本，测定SCC水平，放疗结束1个月后行全腹MRI，依据RESIST标准评价近期疗效，对SCC水 平和近期疗效进行分析。结果 治疗前SCC的水平与肿瘤负荷、临床分期及淋巴结转移有关（P<0.05），与年 龄无关。宫颈癌患者近期疗效与治疗前血清SCC呈负相关（P<0.05）。血清SCC的水平治疗后较治疗前明显降低 （P<0.01）。结论 在宫颈癌患者中，治疗前血清SCC水平与肿瘤负荷、临床分期及淋巴结转移相关，治疗前 SCC水平与近期疗效呈负相关。
Abstract:
Objective To investigate the changes of serum levels of squamous cell carcinoma antigen （SCC）before and after radiochemotherapy in patients with cervical cancer，and to explore the correla-tion between the expression levels and tumor load, short-term efficacy. Methods The clinical data of 142 patients with cervical cancer were retrospectively analyzed. The serum specimens of patients were collected before and after treatment, and the expression leves of SCC were detected by electro-chemiluminescence immunoassay. At 1 month after radiotherapy, whole abdomen MRI was performed. The short-term effects were evaluated according to RESIST criteria. The correlation between SCC lev-el and short term efficacy was analyzed. Results The level of SCC before treatment was correlated with tumor load, clinical stage and lymph node metastasis（P<0.05）, but not with age. The short-term efficacy was negatively correlated with the level of SCC before treatment （P<0.05）. The level of serum SCC was significantly lower after treatment than that before treatment（P<0.01）. Con-clusion In patients with cervical cancer, serum SCC level before treatment was correlated with tu-mor load, clinical stage and lymph node metastasis, and short-term efficacy is negatively correlated with SCC level before treatment.

参考文献/References:

[1] Pakin DM, dray F, Feflay J, et al.Estimating the world ealicer burden: Globocan 2000 [J]．Int J Cancer, 2001,94 (2):153-156．

[2] Keys HM, Bundy BN, Stehman FB,etal. Cisplatin, radi-ation，and adjuvant hysterectomy compared with radiationand adjuvant hysterectomy for bulky stage IB cervical car-cinoma [J]. N Engl J Med, 1999,341(9):708．
[3] Whitney CW, Sause W, Bundy BN,et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-ⅣA carci-noma of the cervix with negative para-aortic lymph nodes： a Gynecologic OncologyGroup and Southwest Oncology Group study [J]. J Clin Oncol,1999,17(5):1339-1348．
[4] 殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国 协和医科大学出版社,2008:1008
[5] Kato H,Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma [J]. Cell Mol-BiolIncl Cyto Enzymol,1979,25(1):51-56．
[6] Kim YT, Yoon BS, Kim JW,et al. Pretreatment levels of serum squamous cell carcinoma antigen and urine poly-amines in women with squamous cell carcinoma of the cer-vix [J]. Int J Gynaecol Ob?stet, 2005,91(1):47-52.
[7] Neunteufel W, Tatra G, Bieglmayer C. Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls [J]. Arch Gynecol Obstet,1989,246(4):243-250.
[8] Brioschi PA, Bischof P, Delafosse C, et al. Squamous-cell carcinoma antigen (SCC- A) values related to clinical outcome of pre- invasive and invasive cervical carcinoma [J]. Int J Cancer, 1991,47(3):376-379.
[9] Senekjian EK, Young JM, Weiser PA,et al. An evalua-tion of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma [J]. Am J Obstet Gyne-col, 1987,157(2):433-439.
[10] Takeshima N, Hirai Y, Katase K, et al. The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer [J]. Gynecol Oncol,1998,68 (3):263-266.
[11] 冯淑瑜,张彦娜,刘建刚.宫颈癌淋巴结转移的高危因素及预后分 析[J].癌症,2005,24(10):1261-1266.
[12] Lin H, ChangChien CC, Huang EY, et al. The role of pretreatment squamous cell carcinoma antigen in predicting nodal metastasis in early stage cervical cancer [J]. Acta Obstet Gynecol Scand,2000,79(2):140-144.
[13] OharaY, Tanaka H, TsunodaM,et al.Assessment of cer-vical cancer radioresponse by serum squamous cell carcino-ma antigen and magnetic resonance imaging [J]. Obstet. Gynecol,2002,100(4):781-787.
[14] Bolger BS, Dabbas M, Lopes A,et al. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma [J]. Gyne-col Oncol, 1997,65(2):309-313.
[15] Bolli JA, Doering DL, Bosscher JR,et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcino-ma of the uterine cervix [J]. Gynecol Oncol,1994,55(2): 169-173.
[16] Strauss HG, Laban C, Lautenschlager C,et al. SCC anti-gen in the serum as an independent prognostic factor in op-erable squamous cell carcinoma of the cervix [J]. Eur J Cancer,2002,38(15):1987-1991.
[17] Ngan HY, Chan SY, Wong LC,et al. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix [J]. Gynecol Oncol,1990,37(2):260-263.
[18] Meier W, Eiermann W, Stieber P,et al. Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy [J]. Gynecol Oncol, 1990,38(1):6-11.
[19] Scambia G, Benedetti P, Foti E,etal. Squamous cell car-cinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervi-cal cancer [J]. J Clin Oncol, 1994,12(11):2309-2316.

[20] Huang EY , Huang YJ, Chanchien CC,et al. Pretreat-ment carcinoembryonic antigen level is a risk factor for pa-ra- aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrentchemo-radiotherapy for squamous cell carcinoma of the uterine cervix [J]. Radiation Oncology, 2012,7(1):13-13.

[21] Liu SC, Huang EY, Hu CF,et al. Pretreatment Factors Associated with Recurrence for Patients with Cervical Can-cer International Federation of Gynecology and Obstetrics Stage IB1 Disease [J]. Gynecol Obstet Invest,2016,81(4): 339-345.

[22] Jeong BK, Huh SJ, Choi DH, et al. Prognostic Value of Different Patterns of Squamous Cell Carcinoma Antigen Level for the Recurrent Cervical Cancer [J]. Cancer Res Treat,2013,45(1):48-54.

[23] Markovina S, Wang S, Henke LE,et al. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer [J]. Br J Cancer, 2018, 118(1):72-78.

[24] Hong JH, Tsai CS, Chang JT,et al. The prognostic sig-nificance of pre-and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by ra-diotherapy [J]. Int J Radiat Oncol Biol Phys, 1998,41(4): 823-830.

[25] Ryuji K, Naoto F, Hiroshi K,et al. Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy [J]. J Gynecol Oncol, 2013,24(4): 313-320.

备注/Memo

备注/Memo:
作者简介：王玲华，硕士，住院医师，研究方向：肿瘤学 通信作者：冯梅，E-mail：m13810494080@163.com
更新日期/Last Update: 2019-07-28